# Digital Twin Patient Agent

**ID:** `biomedical.clinical.digital_twin`
**Version:** 1.0.0
**Status:** Experimental
**Category:** Clinical AI / Personalized Medicine

---

## Overview

The **Digital Twin Patient Agent** creates patient-specific computational models that simulate treatment responses for personalized medicine and clinical trial optimization. Digital twins integrate de-identified patient records, genomic data, imaging scans, and wearable data to predict how specific patients might respond to treatments.

---

## Key Capabilities

### 1. Digital Twin Components

| Component | Data Source | Model Type |
|-----------|-------------|------------|
| **Physiology** | Vitals, labs | Mechanistic ODE |
| **Disease** | EHR history | Survival models |
| **Genomics** | WES/WGS | PRS, pharmacogenomics |
| **Imaging** | CT, MRI | Deep learning |
| **Behavior** | Wearables | Time-series ML |

### 2. Applications

| Use Case | Description | Benefit |
|----------|-------------|---------|
| **Treatment selection** | Compare regimen outcomes | Personalization |
| **Dose optimization** | PK/PD simulation | Safety/efficacy |
| **Trial enrichment** | Patient stratification | Efficiency |
| **Outcome prediction** | Response probability | Decision support |

### 3. Clinical Areas

- **Oncology:** Tumor response prediction
- **Cardiology:** Ablation planning, device optimization
- **Diabetes:** Glucose control simulation
- **Psychiatry:** Medication response prediction

---

## Usage

### Example Prompt

```text
Create a digital twin for a breast cancer patient to predict
treatment response.

Patient data:
- 54-year-old female
- ER+/PR+/HER2- breast cancer, Stage IIB
- Genomic test: Oncotype DX RS = 24
- No major comorbidities
- BMI 28

Compare predicted outcomes for:
1. Endocrine therapy alone
2. Chemotherapy + endocrine therapy
```

### Expected Output

```
## Digital Twin Analysis: Breast Cancer Treatment

### Patient Profile
- **Age:** 54 years
- **Tumor:** ER+/PR+/HER2-, Stage IIB
- **Oncotype DX RS:** 24 (intermediate)
- **Node status:** 1-3 positive

### Digital Twin Model Components

| Component | Data | Model |
|-----------|------|-------|
| Tumor dynamics | Imaging + biomarkers | Growth ODE |
| Treatment response | Genomics + clinical | ML ensemble |
| Toxicity risk | Demographics + comorbidities | Survival model |

### Treatment Comparison

#### Option 1: Endocrine Therapy Alone
```
5-year Outcomes:
- Distant recurrence-free survival: 87%
- Overall survival: 94%
- Quality-adjusted life years: 4.2
- Expected toxicities: Hot flashes (80%), arthralgia (40%)
```

#### Option 2: Chemotherapy + Endocrine
```
5-year Outcomes:
- Distant recurrence-free survival: 91%
- Overall survival: 96%
- Quality-adjusted life years: 3.9
- Expected toxicities: Nausea (60%), neutropenia (30%), neuropathy (20%)
```

### Absolute Benefit Analysis
| Endpoint | ET Alone | Chemo+ET | Absolute Benefit |
|----------|----------|----------|------------------|
| 5y DRFS | 87% | 91% | +4% |
| 5y OS | 94% | 96% | +2% |
| QALY | 4.2 | 3.9 | -0.3 |

### Digital Twin Recommendation
**Marginal benefit from chemotherapy (4% absolute)**

Consider patient preferences:
- If risk-averse → Chemotherapy + endocrine
- If QoL priority → Endocrine alone
- Discuss 4% absolute benefit vs toxicity trade-off
```

---

## References

- **Hernandez-Boussard et al. (2021):** "Digital twins for predictive oncology." *Nature Medicine*
- **Corral-Acero et al. (2020):** "The digital twin to enable the vision of precision cardiology."

---

## Author

**MD BABU MIA**
*Artificial Intelligence Group*
*Icahn School of Medicine at Mount Sinai*
md.babu.mia@mssm.edu
